Skip Navigation

European Heart Journal 2000 21(3):220-229; doi:10.1053/euhj.1999.1999
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (43)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Klamann, A
Right arrow Articles by Nauck, M.A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klamann, A
Right arrow Articles by Nauck, M.A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)

A Klamann, P Sarfert, V Launhardt, G Schulte, W.H Schmiegel and M.A Nauckf1

Department of Medicine, Ruhr-University Knappschafts-Krankenhaus, Bochum, Germany

revised June 7, 1999; accepted June 9, 1999

Abstract

Aims Sulfonylureas may interfere with ‘ischaemic preconditioning’ and worsen the prognosis in diabetic patients with acute myocardial infarction.

Methods and Results Three hundred and fifty-seven non-diabetic patients admitted with acute myocardial infarction to one hospital over 6·5 years (72 deaths, in-hospital mortality 20·2%) were compared to 245 Type 2 diabetic patients categorized as having taken sulfonylureas (glibenclamide 7±3mg.day–1; n=76, 25 deaths=32·9%;P=0·025), not having taken sulfonylureas (n=89, 29 deaths=33·0%;P=0·012), and newly diagnosed as having diabetes (n=80, 20 deaths=25·0%). Survival was significantly different (log-rank test: P=0·03). Increments in creatine kinase and creatine kinaseMBactivity were higher in non-diabetic patients (P<0·01).

Conclusions In-hospital mortality in Type 2 diabetic patients is higher than in non-diabetic patients suffering acute myocardial infarction regardless of whether or not they had been treated with sulfonylureas. Glibenclamide does not enlarge myocardial necroses.

Key Words: Sulfonylureas, ischemic preconditioning, myocardial infarction, mortality, Type 2 diabetes

f1 Correspondence: Prof. Dr med. Michael A. Nauck, Medizinische Universitätsklinik, Ruhr-Universität Bochum, Knappschafts-Krankenhaus, In der Schornau 23-25, D-44892 Bochum, Germany.

References

  1. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19:730–789[Web of Science][Medline]
  2. Knatterud GL, Klimt C, Osborne RK, Meinert CL, Martin DB, Hawkins NBS. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes. 1975;24:65–187
  3. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes. 1972;21:976–979[Web of Science][Medline]
  4. Cornfield J. The University Group Diabetes Program. A further statistical analysis of the mortality findings. JAMA. 1971;217:1676–1687[Abstract/Free Full Text]
  5. Schor S. The University Group Diabetes Program. A statistician looks at the mortality results. JAMA. 1971;217:1673–1675
  6. Ratzmann KP. Eine Analyse von alters- und geschlechtsspezifischer Diabetesprävalenz sowie Behandlungsart: Die Berlin-Studie. Akt Endokr Stoffw. 1991;12:220–223
  7. Aguilar-Bryan L, Nichols CG, Wechsler SW. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268:423–426[Abstract/Free Full Text]
  8. Inagaki N, Gonoi T, Clement JP. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+channels. Neuron. 1996;16:1011–1017[CrossRef][Web of Science][Medline]
  9. Bijlstra PJ, Lutterman JA, Russel FGM, Thien T, Smits P. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia. 1996;39:1083–1090[Web of Science][Medline]
  10. Smits P, Bijlstra PJ, Russel FG, Lutterman JA, Thien T. Cardiovascular effects of sulphonylurea derivatives. Diabetes Res Clin Pract. 1996;31:S55–59
  11. Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia. 1996;39:503–514[Web of Science][Medline]
  12. Brady PA, Terzic A. The sulfonylurea controversy: More questions from the heart. J Am Coll Cardiol. 1998;31:950–956[Abstract/Free Full Text]
  13. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res. 1993;27:617–622[Abstract/Free Full Text]
  14. Tomai F, Crea F, Gaspardone A. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+channel blocker. Circulation. 1994;90:700–705[Abstract/Free Full Text]
  15. Engler RL, Yellon DM. Sulphonylurea KATPblockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation. 1996;94:2297–2301[Free Full Text]
  16. Cleveland JC, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: Two paradoxes revisited. Circulation. 1997;96:29–32[Abstract/Free Full Text]
  17. Cacciapuoti F, Spiezia R, Bianchi U, Lama D, Avino M, Varricchio M. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol. 1991;67:843–847[CrossRef][Web of Science][Medline]
  18. Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron Artery Dis. 1994;5:767–771[Web of Science][Medline]
  19. Lomuscio A, Fiorentini C. Influence of oral antidiabetic treatment on electrocardiac alterations induced by myocardial infarction. Diabetes Res Clin Pract. 1996;31:S21–26
  20. Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care. 1997;20:704–708[Abstract]
  21. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Int Med. 1997;126:296–306[Abstract/Free Full Text]
  22. Miettinen H, Lehto S, Salomaa V. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care. 1998;21:69–75[Abstract]
  23. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care. 1985;8:230–234[Abstract]
  24. Soler NG, Bennett MA, Pentecost BL, Fitzgerald MG, Malins JM. Myocardial infarction in diabetes. Q J Med. 1975;44:125–132[Web of Science][Medline]
  25. Ulvenstam G, Aberg A, Bergstrand R. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes. 1985;34:787–792[Abstract]
  26. N Engl J Med. 1986;314:1465–1471[Abstract]
  27. Anderson JL, Marshall HW, Bray BE. A randomized trial of the intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med. 1983;308:1312–1318[Abstract]
  28. Nauck MA, Sarfert P, Klamann A, Launhardt V, Schulte G, Schmiegel WH. Myocardial infarction in diabetic patients. Relation of survival in infarct size to glibenclamide therapy (abstract). Diabetes. 1998;47:A121
  29. Diabetes Care. 1997;21:S5–S22
  30. Hennekens CH, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction— evidence from clinical trials. N Engl J Med. 1996;335:1660–1667[Free Full Text]
  31. Collins R, Peto R, Baigent C, Sleight P. Aspirin, Heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 1997;336:847–860[Free Full Text]
  32. Lehto S, Pyorala K, Miettinen H. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. J Intern Med. 1994;236:291–297[Web of Science][Medline]
  33. Davis TME, Parsons RW, Broadhurst R, Hobbs M, Jamrozik K. Arrythmias and mortality after myocardial infarction in diabetic patients: Relationship to diabetes treatmen (abstract). Diabetologia. 1996;39:A51
  34. Brady PA, Al-Suwaidi J, Kopeckiy SL, Terzic A. Sulfonylurea and mortality in diabetic patients with myocardial infarction. Circulation. 1998;97:709–710[Free Full Text]
  35. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980;29:41–49[Abstract]
  36. Orlander PR, Goff DC, Morrissey M. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. The Corpus Christi Heart Project. Diabetes. 1994;43:897–902[Abstract]
  37. Woodfield SL, Lundergan CF, Reiner JS. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The GUSTO-1 experience. J Am Coll Cardiol. 1996;28:1661–1669[Abstract]
  38. Lim R, Laskey W. Ischemic preconditioning in unstable coronary syndromes: Evidence for time dependence. J Am Coll Cardiol. 1997;30:1461–1465[Abstract]
  39. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res. 1997;34:248–253[Abstract/Free Full Text]
  40. Lancet. 1998;352:837–853[CrossRef][Web of Science][Medline]
  41. Granger CB, Califf R, Young S. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol. 1993;21:920–925[Abstract]
  42. Chambless L, Keil U, Dobson A. Population versus clinical view of case-fatality from acute coronary heart disease. Circulation. 1997;96:3849–3859[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mayo Clin Proc.Home page
A. M. Arruda-Olson, R. K. Patch III, C. L. Leibson, A. Vella, R. L. Frye, S. A. Weston, J. M. Killian, and V. L. Roger
Effect of Second-Generation Sulfonylureas on Survival in Patients With Diabetes Mellitus After Myocardial Infarction
Mayo Clin. Proc., January 1, 2009; 84(1): 28 - 33.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. E. Inzucchi and D. K. McGuire
New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Circulation, January 29, 2008; 117(4): 574 - 584.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Misaki, X. Mao, Y.-F. Lin, S. Suga, G.-H. Li, Q. Liu, Y. Chang, H. Wang, M. Wakui, and J. Wu
Iptakalim, a Vascular ATP-Sensitive Potassium (KATP) Channel Opener, Closes Rat Pancreatic beta-Cell KATP Channels and Increases Insulin Release
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 871 - 878.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
P. Valensi and G. Slama
Review: Sulphonylureas and cardiovascular risk: facts and controversies
The British Journal of Diabetes & Vascular Disease, July 1, 2006; 6(4): 159 - 165.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Cardiovascular Disease
Diabetes Care, May 1, 2006; 29(5): 1160 - 1166.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. J. Meier, S. Deifuss, A. Klamann, V. Launhardt, W. H. Schmiegel, and M. A. Nauck
Plasma Glucose at Hospital Admission and Previous Metabolic Control Determine Myocardial Infarct Size and Survival in Patients With and Without Type 2 Diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA)
Diabetes Care, October 1, 2005; 28(10): 2551 - 2553.
[Full Text] [PDF]

Home page
 Clin. DiabetesHome page
B. Kimmel and S. E. Inzucchi
Oral Agents for Type 2 Diabetes: An Update
Clin. Diabetes, April 1, 2005; 23(2): 64 - 76.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch
Management of Diabetes and Hyperglycemia in Hospitals
Diabetes Care, February 1, 2004; 27(2): 553 - 591.
[Full Text] [PDF]

Home page
 HeartHome page
J J Meier, B Gallwitz, W E Schmidt, A Mugge, and M A Nauck
Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
Heart, January 1, 2004; 90(1): 9 - 12.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
T.-M. Lee, S.-F. Su, T.-F. Chou, and C.-H. Tsai
Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty
J. Am. Coll. Cardiol., March 6, 2002; 39(5): 871 - 877.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
H. M. O. Farouque, S. G. Worthley, I. T. Meredith, R. A. P. Skyrme-Jones, and M. J. Zhang
Effect of ATP-Sensitive Potassium Channel Inhibition on Resting Coronary Vascular Responses in Humans
Circ. Res., February 8, 2002; 90(2): 231 - 236.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
Z S Kyriakides, S Psychari, N Chrysomallis, M Georgiadis, E Sbarouni, and D T Kremastinos
Type II diabetes does not prevent the recruitment of collateral vessels and the normal reduction of myocardial ischaemia on repeated balloon inflations during angioplasty
Heart, January 1, 2002; 87(1): 61 - 66.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
M. Weih, N. Amberger, S. Wegener, U. Dirnagl, T. Reuter, and K. Einhaupl
Sulfonylurea Drugs Do Not Influence Initial Stroke Severity and In-Hospital Outcome in Stroke Patients With Diabetes
Stroke, September 1, 2001; 32(9): 2029 - 2032.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
P. Spallarossa, M. Schiavo, P. Rossettin, S. Cordone, L. Olivotti, R. Cordera, and C. Brunelli
Sulfonylurea Treatment of Type 2 Diabetic Patients Does Not Reduce the Vasodilator Response to Ischemia
Diabetes Care, April 1, 2001; 24(4): 738 - 742.
[Abstract] [Full Text]

Home page
 Eur Heart JHome page
D.J. Betteridge and L. Close
Diabetes, coronary heart disease and sulphonylureas--not the final word
Eur. Heart J., May 2, 2000; 21(10): 790 - 792.
[PDF]

Home page
 Circ. Res.Home page
H. M. O. Farouque, S. G. Worthley, I. T. Meredith, R. A. P. Skyrme-Jones, and M. J. Zhang
Effect of ATP-Sensitive Potassium Channel Inhibition on Resting Coronary Vascular Responses in Humans
Circ. Res., February 8, 2002; 90(2): 231 - 236.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (43)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Klamann, A
Right arrow Articles by Nauck, M.A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klamann, A
Right arrow Articles by Nauck, M.A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?